Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology

Journal of Neuropathology and Experimental Neurology

Volumn 62, Issue 2, 2003, Pages 111-126

  Reifenberger, Guido ^a   Louis, David N ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brain neoplasms; Chemotherapy; Molecular genetics; Oligodendroglioma; Prognostic factors; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ALLELE; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 7P; CHROMOSOME ABERRATION; CHROMOSOME ARM; CLINICAL EXAMINATION; DIAGNOSTIC IMAGING; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR GENETICS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR GENE; REVIEW;

EID: 0037317982     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/62.2.111     Document Type: Review

References (111)

1. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-64
2. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573-74
3. Perry JR, Louis DN, Cairncross JG. Current treatment of oligodendrogliomas. Arch Neurol 1999;56:434-36
4. Bauman GS, Cairncross JG. Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligoastrocytomas. Semin Radiat Oncol 2001;11:170-80
5. Chinot O. Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 2001;(4 Suppl 13):13-18
6. van den Bent MJ. New perspectives for the diagnosis and treatment of oligodendroglioma. Expert Rev Anticancer Ther 2001;1:348-56
7. Kim L, Hochberg FH, Thornton AF, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996;85:602-7
8. Lu QR, Park JK, Noll E, et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 2001;98:10851-56
9. Hoang-Xuan K, Aguirre-Cruz L, Mokhtari K, Marie Y, Sanson M. OLIG-1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol 2002;28:89-94
10. Marie Y, Sanson M, Mokhtari K, et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001;358:298-300
11. Blümcke I, Becket AJ, Normann S, et al. Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol 2001;60:984-93.
12. Suzuki SO, Kitai R, Llena J, Lee SC, Goldman JE, Shafit-Zagardo B. MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. J Neuropathol Exp Neurol 2002;61:403-12
13. Giannini C, Scheithauer BW, Weaver AL, et al. Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001;60:248-62
14. Burger PC. What is an oligodendroglioma? Brain Pathol 2002;12:257-59
15. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 2002;61:58-63
16. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP. Chapter 2: Oligodendroglial tumours and mixed gliomas. In: Kleihues P, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system. World Health Organization Classification of Tumours. Lyon: IARC Press, 2000;55-70
17. Cairncross JG, Ueki K, Zlatescu C, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
18. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45
19. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-30
20. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-45
21. Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001;57:1278-81
22. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002;20:2495-99
23. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90
24. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-10
25. Zhu JJ, Santarius T, Wu X, et al. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer 1998;21:207-16
26. Husemann K, Wolter M, Büschges R, Boström J, Reifenberger G. Identification of two distinct deleted regions on the short arm of chromosome I and rare mutation of the CDKN2C gene at 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999;58:1041-50
27. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52
28. Iuchi T, Namba H, Iwadate Y, et al. Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 2002;35:170-75
29. INK4c gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 1999;9:639-43
30. He J, Hoang-Xuan K, Marie Y, et al. P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurology 2000;55:867-69
31. Mai M, Huang H, Reed C, et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998;51:359-63
32. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer 2001;85:204-8
33. Bello MJ, de Campos JM, Vaquero J, et al. hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas Cancer Genet Cytogenet 2000;116:142-47
34. Dong S, Pang JC, Hu J, Zhou LF, Ng HK. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 2002;98:370-75
35. Watanabe T, Huang H, Nakamura M, et al. Methylation of thep73 gene in gliomas. Acta Neuropathol (Berl) 2002;104:357-62
36. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002;2:605-15
37. Zaika AI, Slade N, Erster SH, et al. DeltaNp73, A dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-80
38. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002;62:3598-3602
39. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992;52:4277-79
40. von Deimling A, Bender B, Jahnke R, et al. Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q. Cancer Res 1994;54:1397-1401
41. Rosenberg JE, Lisle DK, Burwick JA, et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996;13:2483-85
42. Smith JS, Tachibana I, Lee HK, et al. Mapping of the chromosome 19q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000;29:16-25
43. Smith JS, Tachibana I, Pohl U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 2000;64:44-50
44. Pohl U, Smith JS, Tachibana I, et al. EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins. Genomics 2000;63:255-62
45. Mora J, Cheung NK, Chen L, Qin J, Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res 2001;7:1358-61
46. Yong WH, Chou D, Ueki K, et al. Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 1995;54:622-40
47. Hartmann C, Johnk L, Kitange G, et al. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 2002;62:4100-108
48. Sanson M, Leuraud P, Marie Y, Delattre JY, Hoang-Xuan K. Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas. Ann Neurol 2002;52:105-7
49. Kohda T, Asai A, Kuroiwa Y, et al. Tumor suppressor activity of human imprinted gene PEG3 in a glioma cell line. Genes Cells 2001;6:237-47
50. Maegawa S, Yoshioka H, Itaba N, et al. Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog 2001;31:1-9
51. Johnson MD, Wu X, Aithmitti N, Morrison RS. Peg3/Pw1 is a mediator between p53 and Bax in DNA damage-induced neuronal death. J Biol Chem 2002;277:23000-7
52. Yamaguchi A, Taniguchi M, Hori O, et al. Peg3/Pw1 is involved in p53-mediated cell death pathway in brain ischemia/hypoxia. J Biol Chem 2002;277:623-29
53. Burger PC, Minn AY, Smith JS, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001;14:842-53
54. ink4b) tumor suppressor genes. J Neuropathol Exp Neurol 2001;60:1170-80
55. Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002;8:196-201
56. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (Berl) 2002;103:267-75
57. Sherr CJ. The INK4a/ARF network in tumor suppression. Nat Rev Mol Cell Biol 2001;2:731-36
58. Weber RG, Sabel M, Reifenberger J, et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 1996;13:983-94
59. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-86
60. Kros JM, van Run PR, Alers JC, et al. Genetic aberrations in oligodendroglial tumours: An analysis using comparative genomic hybridization (CGH). J Pathol 1999;188:282-88
61. Jeuken JW, Sprenger SH, Vermeer H, Kappelle AC, Boerman RH, Wesseling P. Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: Clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 2002;96:559-64
62. Jeuken JW, Sprenger SH, Vermeer H, Kappelle AC, Boerman RH, Wesseling P. Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: Clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 2002;96:559-64
63. Bortolotto S, Chiado-Piat L, Cavalla P, et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000;88:554-57
64. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H. Concurrent inactivation of RBI and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 2001;60:1181-89
65. INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77
66. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12
67. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72
68. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-53
69. Duerr EM, Rollbrocker B, Hayashi Y, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998;16:2259-64
70. Jeuken JW, Nelen MR, Vermeer H, et al. PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors. PTEN is only occasionally mutated in one of the two genetic subtypes. Cancer Genet Cytogenet 2000;119:42-47
71. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001;159:359-67
72. Maier D, Comparone D, Taylor E, et al. New deletion in lowgrade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997;15:997-1000
73. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503
74. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996;149:29-35
75. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 2000;48:1103-10
76. Fleming TP, Saxena A, Clark WC, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-53
77. Actor B, Cobbers JM, Büschges R, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 2002;34:416-27
78. Riemenschneider MJ, Büschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from lq32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999;59:6091-96
79. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;5491-95
80. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-1104
81. Müller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-39
82. Jeuken JW, Sprenger SH, Boerman RH, et al. Subtyping of oligoastrocytic tumors by comparative genomic hybridization. J Pathol 2001;194:81-87
83. Dong ZQ, Pang JC, Tong CY, Zhou LF, Ng HK. Clonality of oligoastrocytomas. Hum Pathol 2002;33:528-35
84. Esteller M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 2002;21:5427-40
85. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28
86. Dong SM, Pang JC, Poon WS, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001;60:808-16
87. INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 2001;101:185-89
88. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999;9:349-57
89. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-86
90. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998;58:4515-18
91. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-97
92. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-54
93. 6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics. Cancer Res 1998;58:1068-73
94. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195:41-52
95. Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: An array of possibilities. J Clin Oncol 2002;20:3165-75
96. Fuller GN, Hess KR, Rhee CH, et al. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 2002;12:108-16.
97. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-91
98. Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 2001;61:1825-29
99. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42
100. Mukasa A, Ueki K, Matsumoto S, et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002;21:3961-68
101. Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713-15
102. Kros JM, Pieterman H, van Eden CG, Avezaat CJ. Oligodendroglioma: The Rotterdam-Dijkzigt experience. Neurosurgery 1994; 34:959-66
103. Louis DN, Holland EC, Cairncross JG. Glioma classification: A molecular reappraisal. Am J Pathol 2001;159:779-86
104. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-28
105. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;92:983-90
106. Burger PC, Pearl DK, Aldape K, et al. Small cell architecture A histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 2001;60:1099-1104
107. James CD, Carlbom E, Nordenskjold M, Collins VP, Cavenee WK. Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA 1989;86:2858-62
108. Hartmann C, Johnk L, Sasaki H, Jenkins RB, Louis DN. Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas. Brain Pathol 2002;12:178-82
109. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 2001;158:1253-62
110. Jenkins RB, Curran W, Scott CB, Cairncross G. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol 2001;24:506-8
111. Rubio MP, Correa KM, Ueki K, et al. The putative glioma tumor suppressor gene on Chromosome 19q maps between APOC2 and HRC. Cancer Res 1994;54:4760-63